🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

624 results for “Solid” Clear

  1. "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten

    Bristol-Myers Squibb / Pfizer EEIG

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. Bavencio 20 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Solid Tumors

    phase 3 small molecule active

    1 trial

  3. DS-8201a

    Daiichi Sankyo Europe GmbH

    Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors

    phase 3 small molecule active

    1 trial

  4. Futibatinib, FULVESTRANT

    Taiho Pharma Netherlands B.V.

    Malignant Solid Tumors

    phase 3 small molecule active

    1 trial

  5. Herceptin 150 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Roche Registration Limited

    Solid Malignant Tumors

    phase 3 small molecule active

    1 trial

  6. IP

    Solid Biosciences

    Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  7. Influenza vaccine

    Lxo Ireland Designated Activity Company

    Infection in Solid Organ Transplant Recipients

    phase 3 mab completed

    1 trial

  8. Lenvatinib, Belzutifan, Lenvatinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations

    phase 3 small molecule active

    1 trial

  9. Ociperlimab, Ociperlimab, Pamiparib, Pamiparib, Tislelizumab

    Beone Medicines Ireland Limited

    Solid tumors and hamatological malignancies

    phase 3 small molecule active

    1 trial

  10. SGT-003

    Solid Biosciences

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    2 trials

  11. VERDYE 5 mg/ml poeder voor oplossing voor injectie

    Disc Medicine

    Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)

    phase 3 small molecule active

    1 trial

  12. dactinomycin

    Solid Biosciences

    Sarcoma

    phase 3 mab active

    1 trial

  13. filgrastim

    Solid Biosciences

    Lymphoma

    phase 3 mab active

    2 trials

  14. filgrastim

    Solid Biosciences

    Lung Cancer

    phase 3 mab active

    1 trial

  15. filgrastim

    Solid Biosciences

    Ovarian Cancer

    phase 3 mab completed

    1 trial

  16. maribavir, Maribavir, LIVTENCITY 200 mg film-coated tablets., Maribavir

    Takeda Pharmaceuticals International AG

    Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)

    phase 3 small molecule active

    1 trial

  17. trofosfamide, idarubicin, etoposide

    Solid Biosciences

    Soft Tissue Sarcoma

    phase 3 small molecule completed

    1 trial

  18. -, -, -, MK-1200, -, -

    Merck Sharp and Dohme

    Advanced solid tumor

    phase 2 small molecule active

    1 trial

  19. -, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -

    Pharma Mar S.A.

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  20. 177Lu-DOTA-EB-FAPI radionuclide therapy

    First Tracks Biotherapeutics

    Refractory Solid Tumor

    phase 2 small molecule completed

    1 trial

  21. 5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac

    Enliven Therapeutics

    Solid Tumors, Colorectal Cancer and Breast Cancer

    phase 2 small molecule active

    1 trial

  22. 68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)

    Istituto Gentili S.r.l.

    Solid tumors

    phase 2 other active

    1 trial

  23. A Clinical Trial for Patients with Advanced Cancers

    Corbus Pharmaceuticals Holdings

    Advanced Solid tumour

    phase 2 other active

    1 trial

  24. A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)

    Merck Sharp and Dohme

    Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources